Cingulate Financials

CING Stock  USD 5.04  0.16  3.28%   
Based on the measurements of operating efficiency obtained from Cingulate's historical financial statements, Cingulate is not in a good financial situation at this time. It has a very high odds of going through financial crisis in February. At this time, Cingulate's Accounts Payable is most likely to decrease significantly in the upcoming years. The Cingulate's current Cash is estimated to increase to about 14.7 M, while Short and Long Term Debt Total is projected to decrease to roughly 3.6 M.
 
Covid
 
Interest Hikes

Cingulate Balance Sheet Chart

At this time, Cingulate's Accounts Payable is most likely to decrease significantly in the upcoming years. The Cingulate's current Cash is estimated to increase to about 14.7 M, while Short and Long Term Debt Total is projected to decrease to roughly 3.6 M.
Key indicators impacting Cingulate's financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Current Ratio3.782.93
Significantly Up
Slightly volatile
Investors should never underestimate Cingulate's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Cingulate's cash flow, debt, and profitability to make informed and accurate decisions about investing in Cingulate.

Net Income

(14.69 Million)

  
Build AI portfolio with Cingulate Stock
Understanding current and past Cingulate Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Cingulate's financial statements are interrelated, with each one affecting the others. For example, an increase in Cingulate's assets may result in an increase in income on the income statement.

Cingulate Stock Summary

Cingulate competes with Allarity Therapeutics, Lexaria Bioscience, Lixte Biotechnology, Kairos Pharma, and Synlogic. Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficithyperactivity disorder. The company was founded in 2012 and is headquartered in Kansas City, Kansas. Cingulate operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 16 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS17248W3034
Business Address1901 West 47th
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.cingulate.com
Phone913 942 2300
CurrencyUSD - US Dollar

Cingulate Key Financial Ratios

Cingulate Key Balance Sheet Accounts

202120222023202420252026 (projected)
Total Assets22.9M11.4M3.5M14.9M17.1M11.7M
Other Current Liab(15.1K)894.6K1.5M839.6K965.6K890.1K
Net Debt(15.3M)509.8K3.5M(7.1M)(6.4M)(6.1M)
Accounts Payable264.7K762.4K5.2M1.3M1.5M1.9M
Cash16.5M5.4M52.4K12.2M14.0M14.7M
Net Receivables690.2K234.4K14.6K26.3K23.7K22.5K
Other Current Assets1.7M2.2M511.6K423.2K486.6K462.3K
Total Liab2.0M7.5M10.4M7.4M8.5M6.7M
Net Invested Capital20.8M8.9M(3.9M)12.4M14.3M7.5M
Total Current Assets18.9M7.9M578.6K12.7M14.6M7.8M
Net Working Capital17.7M856.9K(9.6M)7.7M8.8M9.3M
Short Term Debt325.8K5.4M3.4M2.7M3.1M2.4M
Common Stock1.1K61.010.0340.0306.0290.7
Retained Earnings(51.7M)(69.4M)(92.9M)(108.5M)(97.6M)(102.5M)

Cingulate Key Income Statement Accounts

202120222023202420252026 (projected)
Net Interest Income(30.6K)(174.5K)(768.2K)99.2K89.3K93.8K
Interest Expense33.4K174K776K99K113.9K208.5K
Gross Profit(808.4K)(622.0K)(582.9K)(653.1K)(587.8K)(617.2K)
Operating Income(20.7M)(17.5M)(22.8M)(15.6M)(14.1M)(14.8M)
Ebit(20.7M)(17.5M)(23.5M)(15.5M)(14.0M)(14.7M)
Research Development8.4M9.0M15.5M9.4M10.9M10.4M
Ebitda(19.9M)(17.1M)(23.0M)(14.9M)(13.4M)(14.1M)
Cost Of Revenue808.4K622.0K582.9K653.1K751.1K676.1K
Income Before Tax(20.7M)(17.7M)(23.5M)(15.5M)(14.0M)(14.7M)
Net Income(20.7M)(17.9M)(23.5M)(15.5M)(14.0M)(14.7M)
Income Tax Expense30.5K174K2.0(263.0)(302.45)(287.33)

Cingulate Key Cash Accounts

202120222023202420252026 (projected)
Investments(814.7K)(152.7K)(180.2K)(211.8K)(190.6K)(181.1K)
Change In Cash15.3M(11.1M)(5.3M)12.2M14.0M14.7M
Net Borrowings(936.6K)5.0M3.0M4.9M5.7M6.0M
Free Cash Flow(11.2M)(16.0M)(15.3M)(18.7M)(16.8M)(17.6M)
Depreciation708.3K394.0K582.9K653.1K751.1K583.6K
Other Non Cash Items16.3M798.0K(27.8M)995.5K895.9K940.7K
Capital Expenditures814.7K153.4K224.1K211.8K190.6K376.3K
Net Income(20.7M)(17.7M)(23.5M)(15.5M)(14.0M)(14.7M)
End Period Cash Flow16.5M5.4M52.4K12.2M14.0M14.7M

Cingulate Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Cingulate's current stock value. Our valuation model uses many indicators to compare Cingulate value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cingulate competition to find correlations between indicators driving Cingulate's intrinsic value. More Info.
Cingulate is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Cingulate's Return On Equity is most likely to increase significantly in the upcoming years. Comparative valuation analysis is a catch-all technique that is used if you cannot value Cingulate by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Most indicators from Cingulate's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cingulate current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cingulate. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
For more detail on how to invest in Cingulate Stock please use our How to Invest in Cingulate guide.The Cingulate's current Issuance Of Capital Stock is estimated to increase to about 31.2 M, while Selling General Administrative is projected to decrease to roughly 7.1 M.
 2023 2024 2025 2026 (projected)
Total Operating Expenses22.2M15.0M17.2M16.9M
Cost Of Revenue582.9K653.1K751.1K676.1K

Cingulate fundamental ratios Correlations

0.40.1-0.010.920.7-0.540.16-0.96-0.560.94-0.560.470.940.560.50.18-0.70.550.730.020.990.770.99-0.660.95
0.40.610.70.060.81-0.840.14-0.21-0.020.48-0.840.550.48-0.340.680.18-0.790.30.790.80.410.730.47-0.650.23
0.10.610.8-0.20.67-0.660.69-0.030.310.23-0.690.360.23-0.340.5-0.18-0.680.060.670.760.070.650.17-0.24-0.05
-0.010.70.8-0.370.7-0.660.160.120.610.12-0.670.250.12-0.430.46-0.26-0.670.140.620.96-0.060.590.07-0.55-0.22
0.920.06-0.2-0.370.38-0.180.09-0.93-0.730.79-0.20.220.790.780.190.12-0.390.550.42-0.370.930.470.88-0.40.93
0.70.810.670.70.38-0.860.24-0.570.010.72-0.880.480.720.090.65-0.09-0.950.480.980.70.660.950.75-0.820.49
-0.54-0.84-0.66-0.66-0.18-0.86-0.260.47-0.12-0.691.0-0.83-0.690.33-0.92-0.360.9-0.02-0.92-0.78-0.5-0.85-0.610.71-0.42
0.160.140.690.160.090.24-0.26-0.2-0.20.27-0.30.290.27-0.030.310.03-0.34-0.010.320.110.170.40.170.220.2
-0.96-0.21-0.030.12-0.93-0.570.47-0.20.52-0.940.49-0.51-0.94-0.58-0.51-0.250.63-0.41-0.640.1-0.95-0.68-0.950.59-0.97
-0.56-0.020.310.61-0.730.01-0.12-0.20.52-0.43-0.11-0.05-0.43-0.530.05-0.260.01-0.44-0.040.56-0.64-0.08-0.51-0.09-0.66
0.940.480.230.120.790.72-0.690.27-0.94-0.43-0.70.71.00.340.730.37-0.810.380.790.170.920.840.95-0.710.94
-0.56-0.84-0.69-0.67-0.2-0.881.0-0.30.49-0.11-0.7-0.81-0.70.29-0.91-0.320.92-0.06-0.94-0.78-0.53-0.88-0.630.72-0.43
0.470.550.360.250.220.48-0.830.29-0.51-0.050.7-0.810.7-0.40.970.79-0.65-0.310.640.440.450.620.51-0.470.53
0.940.480.230.120.790.72-0.690.27-0.94-0.431.0-0.70.70.340.730.37-0.810.380.790.170.920.840.95-0.710.94
0.56-0.34-0.34-0.430.780.090.33-0.03-0.58-0.530.340.29-0.40.34-0.38-0.43-0.010.690.02-0.590.570.120.5-0.120.55
0.50.680.50.460.190.65-0.920.31-0.510.050.73-0.910.970.73-0.380.64-0.8-0.160.770.60.470.750.55-0.620.51
0.180.18-0.18-0.260.12-0.09-0.360.03-0.25-0.260.37-0.320.790.37-0.430.64-0.1-0.520.1-0.020.20.080.18-0.060.38
-0.7-0.79-0.68-0.67-0.39-0.950.9-0.340.630.01-0.810.92-0.65-0.81-0.01-0.8-0.1-0.39-0.96-0.68-0.66-0.97-0.750.83-0.57
0.550.30.060.140.550.48-0.02-0.01-0.41-0.440.38-0.06-0.310.380.69-0.16-0.52-0.390.34-0.020.570.430.53-0.460.41
0.730.790.670.620.420.98-0.920.32-0.64-0.040.79-0.940.640.790.020.770.1-0.960.340.670.70.960.8-0.770.56
0.020.80.760.96-0.370.7-0.780.110.10.560.17-0.780.440.17-0.590.6-0.02-0.68-0.020.67-0.020.60.11-0.56-0.18
0.990.410.07-0.060.930.66-0.50.17-0.95-0.640.92-0.530.450.920.570.470.2-0.660.570.7-0.020.730.99-0.610.95
0.770.730.650.590.470.95-0.850.4-0.68-0.080.84-0.880.620.840.120.750.08-0.970.430.960.60.730.81-0.770.63
0.990.470.170.070.880.75-0.610.17-0.95-0.510.95-0.630.510.950.50.550.18-0.750.530.80.110.990.81-0.70.92
-0.66-0.65-0.24-0.55-0.4-0.820.710.220.59-0.09-0.710.72-0.47-0.71-0.12-0.62-0.060.83-0.46-0.77-0.56-0.61-0.77-0.7-0.53
0.950.23-0.05-0.220.930.49-0.420.2-0.97-0.660.94-0.430.530.940.550.510.38-0.570.410.56-0.180.950.630.92-0.53
Click cells to compare fundamentals

Cingulate Account Relationship Matchups

Cingulate fundamental ratios Accounts

202120222023202420252026 (projected)
Total Assets22.9M11.4M3.5M14.9M17.1M11.7M
Other Current Liab(15.1K)894.6K1.5M839.6K965.6K890.1K
Net Debt(15.3M)509.8K3.5M(7.1M)(6.4M)(6.1M)
Accounts Payable264.7K762.4K5.2M1.3M1.5M1.9M
Cash16.5M5.4M52.4K12.2M14.0M14.7M
Net Receivables690.2K234.4K14.6K26.3K23.7K22.5K
Other Current Assets1.7M2.2M511.6K423.2K486.6K462.3K
Total Liab2.0M7.5M10.4M7.4M8.5M6.7M
Net Invested Capital20.8M8.9M(3.9M)12.4M14.3M7.5M
Total Current Assets18.9M7.9M578.6K12.7M14.6M7.8M
Net Working Capital17.7M856.9K(9.6M)7.7M8.8M9.3M
Short Term Debt325.8K5.4M3.4M2.7M3.1M2.4M
Common Stock1.1K61.010.0340.0306.0290.7
Retained Earnings(51.7M)(69.4M)(92.9M)(108.5M)(97.6M)(102.5M)
Today, most investors in Cingulate Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Cingulate's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Cingulate growth as a starting point in their analysis.

Price Earnings To Growth Ratio

0.0137

At this time, Cingulate's Price Earnings To Growth Ratio is most likely to slightly decrease in the upcoming years.

Cingulate January 27, 2026 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Cingulate help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Cingulate. We use our internally-developed statistical techniques to arrive at the intrinsic value of Cingulate based on widely used predictive technical indicators. In general, we focus on analyzing Cingulate Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Cingulate's daily price indicators and compare them against related drivers.

Complementary Tools for Cingulate Stock analysis

When running Cingulate's price analysis, check to measure Cingulate's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cingulate is operating at the current time. Most of Cingulate's value examination focuses on studying past and present price action to predict the probability of Cingulate's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cingulate's price. Additionally, you may evaluate how the addition of Cingulate to your portfolios can decrease your overall portfolio volatility.
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Transaction History
View history of all your transactions and understand their impact on performance
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Equity Valuation
Check real value of public entities based on technical and fundamental data
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Bonds Directory
Find actively traded corporate debentures issued by US companies
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum